Drug Target Elucidation Through Isolation and Analysis of Drug-Resistant Mutants in Cryptococcus Neoformans

Overview

Journal Methods Mol Biol

Specialty Molecular Biology

Date 2023 Apr 6

PMID 37024699

Authors

Michael J Hoy

Joseph Heitman

Affiliations

Soon will be listed here.

Abstract

Drug target identification is an essential component to antifungal drug development. Many methods, including large chemical library screening, natural product screening, and drug repurposing efforts, can identify compounds with favorable in vitro antifungal activity. However, these approaches will often identify compounds with no known mechanism of action. Herein, we describe a method utilizing the human fungal pathogen Cryptococcus neoformans to identify antifungal drug targets through the isolation of spontaneous resistant mutants, antifungal testing, whole-genome sequencing, and variant analysis.

References

Odom A, Muir S, Lim E, Toffaletti D, Perfect J, Heitman J . Calcineurin is required for virulence of Cryptococcus neoformans. EMBO J. 1997; 16(10):2576-89. PMC: 1169869. DOI: 10.1093/emboj/16.10.2576. View

Roemer T, Xu D, Singh S, Parish C, Harris G, Wang H . Confronting the challenges of natural product-based antifungal discovery. Chem Biol. 2011; 18(2):148-64. DOI: 10.1016/j.chembiol.2011.01.009. View

Friedman R, Gish S, Brown H, Brier L, Howard N, Doering T . Unintended Side Effects of Transformation Are Very Rare in . G3 (Bethesda). 2018; 8(3):815-822. PMC: 5844303. DOI: 10.1534/g3.117.300357. View

Huang D, LeBlanc E, Shekhar-Guturja T, Robbins N, Krysan D, Pizarro J . Design and Synthesis of Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors. J Med Chem. 2019; 63(5):2139-2180. PMC: 7069776. DOI: 10.1021/acs.jmedchem.9b00826. View

Perlatti B, Harris G, Nichols C, Ekanayake D, Alspaugh J, Gloer J . Campafungins: Inhibitors of and Hyphal Growth. J Nat Prod. 2020; 83(9):2718-2726. PMC: 7530089. DOI: 10.1021/acs.jnatprod.0c00641. View

Nielsen K, Cox G, Wang P, Toffaletti D, Perfect J, Heitman J . Sexual cycle of Cryptococcus neoformans var. grubii and virulence of congenic a and alpha isolates. Infect Immun. 2003; 71(9):4831-41. PMC: 187335. DOI: 10.1128/IAI.71.9.4831-4841.2003. View

Whitesell L, Robbins N, Huang D, McLellan C, Shekhar-Guturja T, LeBlanc E . Structural basis for species-selective targeting of Hsp90 in a pathogenic fungus. Nat Commun. 2019; 10(1):402. PMC: 6345968. DOI: 10.1038/s41467-018-08248-w. View

Janbon G, Ormerod K, Paulet D, Byrnes 3rd E, Yadav V, Chatterjee G . Analysis of the genome and transcriptome of Cryptococcus neoformans var. grubii reveals complex RNA expression and microevolution leading to virulence attenuation. PLoS Genet. 2014; 10(4):e1004261. PMC: 3990503. DOI: 10.1371/journal.pgen.1004261. View

Boyce K, Wang Y, Verma S, Shakya V, Xue C, Idnurm A . Mismatch Repair of DNA Replication Errors Contributes to Microevolution in the Pathogenic Fungus . mBio. 2017; 8(3). PMC: 5449657. DOI: 10.1128/mBio.00595-17. View

10.

Heitman J, Movva N, Hall M . Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 1991; 253(5022):905-9. DOI: 10.1126/science.1715094. View

11.

Hartland K, Pu J, Palmer M, Dandapani S, Moquist P, Munoz B . High-Throughput Screen in Identifies a Novel Molecular Scaffold That Inhibits Cell Wall Integrity Pathway Signaling. ACS Infect Dis. 2016; 2(1):93-102. PMC: 4709821. DOI: 10.1021/acsinfecdis.5b00111. View

12.

Sun S, Priest S, Heitman J . Cryptococcus neoformans Mating and Genetic Crosses. Curr Protoc Microbiol. 2019; 53(1):e75. PMC: 6586516. DOI: 10.1002/cpmc.75. View

13.

de Oliveira H, Monteiro M, Rossi S, Peman J, Ruiz-Gaitan A, Mendes-Giannini M . Identification of Off-Patent Compounds That Present Antifungal Activity Against the Emerging Fungal Pathogen . Front Cell Infect Microbiol. 2019; 9:83. PMC: 6454888. DOI: 10.3389/fcimb.2019.00083. View

14.

McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A . The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20(9):1297-303. PMC: 2928508. DOI: 10.1101/gr.107524.110. View

15.

Berman J, Krysan D . Drug resistance and tolerance in fungi. Nat Rev Microbiol. 2020; 18(6):319-331. PMC: 7231573. DOI: 10.1038/s41579-019-0322-2. View

16.

Wambaugh M, Denham S, Ayala M, Brammer B, Stonhill M, Brown J . Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections. Elife. 2020; 9. PMC: 7200157. DOI: 10.7554/eLife.54160. View

17.

Desjardins C, Giamberardino C, Sykes S, Yu C, Tenor J, Chen Y . Population genomics and the evolution of virulence in the fungal pathogen . Genome Res. 2017; 27(7):1207-1219. PMC: 5495072. DOI: 10.1101/gr.218727.116. View

18.

Robbins N, Wright G, Cowen L . Antifungal Drugs: The Current Armamentarium and Development of New Agents. Microbiol Spectr. 2016; 4(5). DOI: 10.1128/microbiolspec.FUNK-0002-2016. View

19.

Butts A, DiDone L, Koselny K, Baxter B, Chabrier-Rosello Y, Wellington M . A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis. Eukaryot Cell. 2012; 12(2):278-87. PMC: 3571299. DOI: 10.1128/EC.00314-12. View

20.

Li H . A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. Bioinformatics. 2011; 27(21):2987-93. PMC: 3198575. DOI: 10.1093/bioinformatics/btr509. View